Total Payments
$5,223
2024 Payments
$459.70
Companies
12
Transactions
247
Medicare Patients
1,394
Medicare Billing
$178,940
Payment Breakdown by Category
Food & Beverage$5,036 (96.4%)
Education$186.58 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,036 | 238 | 96.4% |
| Education | $186.58 | 9 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,332 | 82 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,146 | 54 | $0 (2024) |
| Lilly USA, LLC | $828.01 | 58 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $763.01 | 18 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $429.15 | 7 | $0 (2024) |
| Amgen Inc. | $169.68 | 6 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $162.95 | 11 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $159.30 | 4 | $0 (2021) |
| Astellas Pharma US Inc | $99.99 | 1 | $0 (2021) |
| Bayer Healthcare Pharmaceuticals Inc. | $64.87 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $459.70 | 22 | Lilly USA, LLC ($146.09) |
| 2023 | $356.40 | 15 | Lilly USA, LLC ($164.61) |
| 2022 | $222.60 | 12 | Novo Nordisk Inc ($141.65) |
| 2021 | $717.04 | 27 | Novo Nordisk Inc ($245.65) |
| 2020 | $396.59 | 20 | Novo Nordisk Inc ($175.20) |
| 2019 | $1,544 | 71 | AstraZeneca Pharmaceuticals LP ($385.39) |
| 2018 | $781.73 | 40 | AstraZeneca Pharmaceuticals LP ($226.97) |
| 2017 | $745.06 | 40 | AstraZeneca Pharmaceuticals LP ($432.07) |
All Payment Transactions
247 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Cardio-renal | ||||||
| 09/06/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Inflammation | ||||||
| 08/14/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Diabetes | ||||||
| 08/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Diabetes | ||||||
| 08/09/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $4.24 | General |
| Category: Diabetes | ||||||
| 07/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: Cardiology | ||||||
| 07/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $124.56 | General |
| Category: DIABETES | ||||||
| 06/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Obesity | ||||||
| 05/22/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $4.15 | General |
| Category: Diabetes | ||||||
| 05/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Respiratory | ||||||
| 04/30/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Diabetes | ||||||
| 04/29/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Obesity | ||||||
| 04/19/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Inflammation | ||||||
| 04/02/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Diabetes | ||||||
| 03/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: Diabetes | ||||||
| 03/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Cardio-renal | ||||||
| 03/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $3.80 | General |
| Category: Diabetes | ||||||
| 03/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Diabetes | ||||||
| 02/13/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Diabetes | ||||||
| 01/26/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Inflammation | ||||||
| 01/24/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: Diabetes | ||||||
| 01/24/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $1.78 | General |
| Category: Diabetes | ||||||
| 12/28/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: Diabetes | ||||||
| 12/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: DIABETES | ||||||
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 265 | 976 | $89,375 | $36,325 |
| 2022 | 7 | 285 | 1,024 | $102,352 | $44,620 |
| 2021 | 7 | 331 | 972 | $97,563 | $47,218 |
| 2020 | 9 | 513 | 1,179 | $133,403 | $50,776 |
Total Patients
1,394
Total Services
4,151
Medicare Billing
$178,940
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 346 | $61,554 | $25,818 | 41.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 86 | $17,200 | $9,651 | 56.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 87 | $5,481 | $773.87 | 14.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 32 | 106 | $2,756 | $36.61 | 1.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 43 | 293 | $1,184 | $24.60 | 2.1% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 11 | 58 | $1,200 | $21.89 | 1.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 110 | 436 | $74,708 | $33,767 | 45.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 87 | $17,292 | $9,641 | 55.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 40 | 81 | $5,040 | $783.04 | 15.5% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2022 | 14 | 17 | $340.00 | $339.40 | 99.8% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 14 | 80 | $1,536 | $35.58 | 2.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 29 | 94 | $2,444 | $34.26 | 1.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 34 | 229 | $992.00 | $19.78 | 2.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 136 | 455 | $71,890 | $35,403 | 49.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 52 | 81 | $16,032 | $9,401 | 58.6% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2021 | 28 | 85 | $1,710 | $1,705 | 99.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 48 | 72 | $4,493 | $651.42 | 14.5% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 24 | 63 | $1,614 | $22.75 | 1.4% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2021 | 13 | 60 | $1,200 | $19.59 | 1.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 30 | 156 | $624.00 | $15.71 | 2.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 126 | 247 | $49,249 | $22,410 | 45.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 128 | 314 | $49,612 | $19,470 | 39.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 86 | 145 | $21,758 | $6,480 | 29.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $2,475 | $1,066 | 43.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 65 | 93 | $5,511 | $772.24 | 14.0% |
About Dr. Samuel Olaleye, MD
Dr. Samuel Olaleye, MD is a Internal Medicine healthcare provider based in Newton, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821006644.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Olaleye, MD has received a total of $5,223 in payments from pharmaceutical and medical device companies, with $459.70 received in 2024. These payments were reported across 247 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($5,036).
As a Medicare-enrolled provider, Olaleye has provided services to 1,394 Medicare beneficiaries, totaling 4,151 services with total Medicare billing of $178,940. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Newton, MS
- Active Since 08/04/2006
- Last Updated 10/23/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821006644
Products in Payments
- FARXIGA (Drug) $902.44
- Ozempic (Drug) $571.45
- XARELTO (Drug) $550.41
- JARDIANCE (Drug) $508.82
- TRULICITY (Drug) $460.58
- Tresiba (Drug) $284.04
- MOUNJARO (Drug) $251.36
- INVOKANA (Drug) $212.60
- ELIQUIS (Drug) $159.30
- Wegovy (Drug) $134.58
- JANUVIA (Drug) $120.59
- Victoza (Drug) $119.09
- RYBELSUS (Drug) $115.56
- SYMBICORT (Drug) $110.37
- Repatha (Biological) $102.64
- Saxenda (Drug) $67.03
- Kerendia (Drug) $64.87
- Otezla (Drug) $56.01
- SOLIQUA 100/33 (Drug) $53.25
- BELSOMRA (Drug) $42.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Newton
Dr. Frances Ferguson, M.d, M.D
Internal Medicine — Payments: $53,760
Internal Medicine $53,760
Dr. Tze Chan, Do, DO
Internal Medicine — Payments: $17,371
Internal Medicine $17,371
Charles Safran, M.d, M.D
Internal Medicine — Payments: $12,125
Internal Medicine $12,125
Dr. Gerald Cioce, M.d, M.D
Internal Medicine — Payments: $9,647
Internal Medicine $9,647
Dr. Nick Debitetto, D.o, D.O
Internal Medicine — Payments: $5,380
Internal Medicine $5,380
Dr. Damir Ljuboja, Md, Mba, MD, MBA
Internal Medicine — Payments: $3,829
Internal Medicine $3,829